Graviton Signs an Exclusive Worldwide License Agreement with Beijing Tide for TDI01

 Graviton Signs an Exclusive Worldwide License Agreement with Beijing Tide for TDI01

Graviton Signs an Exclusive Worldwide License Agreement with Beijing Tide for TDI01

Shots:

  • Beijing Tide to receive up to $517.5M including up front, development, regulatory and sales milestone along with royalties and an option for a revenue-sharing arrangement for certain developed products
  • Graviton to get exclusive development and commercialization rights for TDI01 in all territories (Ex- China)
  • TDI01 is a targeted inhibitor of ROCK2 is currently being evaluated in a P-I study in the US for the treatment of IPF. The company expect to develop TDI01 for the treatment of various serious diseases

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post